NIFTY 50

Glenmark launches Favipiravir for treatment of mild to moderate COVID-19 patients

Updated : June 22, 2020 09:47 AM IST

Glenmark’s Fabiflu is the first oral Favipiravir-approved medication for the treatment of COVID-19 and has been launched in few centers.
Fabiflu, available as a 200 mg tablet, has been priced at Rs 103 per tablet.
Favipiravir is also approved for compassionate use in Japan and nearly 2,050 patients have already been administered Favipiravir.

You May Also Like

Live TV

recommended for you